• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Curr Opin Virol . Broad neutralizing antibody-based strategies to tackle influenza

tetano

Editor, Senior Moderator
Curr Opin Virol


. 2022 Feb 4;53:101207.
doi: 10.1016/j.coviro.2022.101207. Online ahead of print.
Broad neutralizing antibody-based strategies to tackle influenza


Xiaoyu Sun[SUP] 1 [/SUP], Zhiyang Ling[SUP] 1 [/SUP], Zhuo Yang[SUP] 1 [/SUP], Bing Sun[SUP] 2 [/SUP]



Affiliations

Abstract

Influenza viruses cause occasional pandemics and annual epidemics, thus persist as a threat to human society. The high variability of viral envelope proteins resulting from antigenic shift and antigenic drift allows influenza viruses to escape human herd immunity. During the past decade, along with the breakthroughs of human monoclonal antibody technologies, many broad reactive monoclonal antibodies (mAbs) that neutralize diverse influenza subtypes have been isolated and characterized. The achievements in this field have provided potential candidates of anti-influenza therapeutics and shed light on the design of universal influenza vaccines. Here, we review the broad neutralizing antibodies (bnAbs) targeting the virus surface proteins, summarize their epitopes, broad spectrum and immunological mechanisms of action and discuss the design of universal influenza vaccines inspired by bnAbs.
 
Back
Top